TABLE 3.

Secondary Outcomes

Outcome	Patient groupa		P value	RR (95% CI)
	Clopidogrel (n=40)	Control (n=80)
Coronary ischemia
Any coronary ischemia	8 (20)	10 (13)	.28	1.60 (0.68-3.74)
Angina	1 (3)	0 (0)	.33	NR
Acute coronary syndrome	0 (0)	0 (0)
Troponin leak	0 (0)	4 (5)	.30	NR
NSTEMI	4 (10)	5 (6)	.48	1.60 (0.45-5.63)
STEMI	1 (3)	0 (0)	.33	NR
Other	2 (5)	1 (1)	.26	4.00 (0.37-42.80)
Cerebral ischemia
Stroke	1 (3)	0 (0)	.33	NR
TIA	0 (0)	0 (0)
Limb ischemia	1 (3)	0 (0)	.33	NR
Venous thromboembolic disease
In-hospital DVT	1 (3)	0 (0)	.33	NR
In-hospital PE	0 (0)	0 (0)
DVT within 6 wks of discharge	1 (3)	2 (3)	1.00	1.00 (0.09-10.70)
PE within 6 wks of discharge	0 (0)	1 (1)	1.00	NR
Infectionb	2 (5)	2 (3)	.60	2.00 (0.29-13.68)
Reoperationc	3 (8)	6 (8)	1.00	1.00 (0.26-3.79)
Combined complication outcomed	12 (30)	18 (23)	.38	1.33 (0.71-2.49)

DVT = deep venous thrombosis; NSTEMI = non–ST-segment elevation myocardial infarction; PE = pulmonary embolism; RR = relative risk; STEMI = ST-segment elevation myocardial infarction; TIA = transient ischemic attack.

^aValues are No. of patients (%).

^bSeptic arthritis within 30 days of surgery.

^cReoperation on affected hip within 1 year of surgery.

^dPatients could have more than 1 complication. In the clopidogrel cohort, 12 patients had 17 complications. In the control cohort, 18 patients had 21 complications.

NR: Relative risk not reported since either no patient in the clopidogrel cohort or no patient in the control cohort had the outcome of interest